Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

about

Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.Use of biologics for psoriasis in Central and Eastern European countries.Biosimilars for the management of rheumatoid arthritis: economic considerations.EQ-5D in Central and Eastern Europe: 2000-2015.

P2860

Q35069447-1B0DBCDE-ECEF-4892-8733-F07B1CDF1A63 Q38586836-3B66EF42-CC42-4484-9A66-F49DBBE76065 Q38591281-1A1AB5A1-72F8-483D-ABDC-861178FE0FFF Q38912637-82458118-F829-42F1-8797-DCDFA139FA9E

P2860

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

Item

http://www.wikidata.org/entity/Q38212140

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Transferability of results of ...... nd Eastern European countries.

@en

type

Item

label

Transferability of results of ...... nd Eastern European countries.

@en

prefLabel

Transferability of results of ...... nd Eastern European countries.

@en

P1476

Transferability of results of ...... nd Eastern European countries.

@en

P2093

Fanni Rencz

http://www.w3.org/2001/XMLSchema#string

László Gulácsi

http://www.w3.org/2001/XMLSchema#string

Márta Péntek

http://www.w3.org/2001/XMLSchema#string

Noémi V Hevér

http://www.w3.org/2001/XMLSchema#string

Petra Baji

http://www.w3.org/2001/XMLSchema#string

Valentin Brodszky

http://www.w3.org/2001/XMLSchema#string

P2860

Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.

Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

The diffusion of health economics knowledge in Europe : The EURONHEED (European Network of Health Economics Evaluation Database) project.

The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.

Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials.

Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

Economic evaluation of systemic therapies for moderate to severe psoriasis.

P2888

s10198-014-0591-7

P304

S27-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10198-014-0591-7

http://www.w3.org/2001/XMLSchema#string

P478

15 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Ruth Lopert

P577

2014-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262382069

http://www.w3.org/2001/XMLSchema#string

P698

24832833

http://www.w3.org/2001/XMLSchema#string

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

about

P2860

P2860

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P698